Trial reportEuropean journal of human genetics : EJHG2021
Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research.
Trial report in European journal of human genetics : EJHG, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 50 citations in OpenAlex.
- Article
- Midkine (MDK) in cancer and drug resistance: from inflammation to therapy.Discover oncology · 2025Review
- SARS-CoV-2 and Dysphagia: A Retrospective Analysis of COVID-19 Patients with Swallowing Disorders.Dysphagia · 2025Article
- Host genetics and COVID-19 severity: increasing the accuracy of latest severity scores by Boolean quantum features.Frontiers in genetics · 2024Article
- Article
- CYP19A1 mediates severe SARS-CoV-2 disease outcome in males.Cell reports. Medicine · 2023Article
- Predictive Role of Cytokine and Adipokine Panel in Hospitalized COVID-19 Patients: Evaluation of Disease Severity, Survival and Lung Sequelae.International journal of molecular sciences · 2023Article
- Ultra-rare RTEL1 gene variants associate with acute severity of COVID-19 and evolution to pulmonary fibrosis as a specific long COVID disorder.Respiratory research · 2023Article
- MR-proADM as Prognostic Factor of Outcome in COVID-19 Patients.Biomedicines · 2023Article
- Autophagy in Inflammatory Response against SARS-CoV-2.International journal of molecular sciences · 2023Review
- Markers of Bronchiolitis Obliterans Syndrome after Lung Transplant: Between Old Knowledge and Future Perspective.Biomedicines · 2022Review
- Gain- and Loss-of-FunctionCells · 2022Article
- An explainable model of host genetic interactions linked to COVID-19 severity.Communications biology · 2022Article
- COVID-19: a challenge and an opportunity.European journal of human genetics : EJHG · 2022Article
- The polymorphism L412F inAutophagy · 2022Article
- Carriers ofViruses · 2022Article
- Common Molecular Pathways Between Post-COVID19 Syndrome and Lung Fibrosis: A Scoping Review.Frontiers in pharmacology · 2022Article
- Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity.Human genetics · 2022Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Within the GEN-COVID Multicenter Study, biospecimens from more than 1000 SARS-CoV-2 positive individuals have thus far been collected in the GEN-COVID Biobank (GCB). Sample types include whole blood, plasma, serum, leukocytes, and DNA. The GCB links samples to detailed clinical data available in the GEN-COVID Patient Registry (GCPR). It includes hospitalized patients (74.25%), broken down into intubated, treated by CPAP-biPAP, treated with O
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.